Global X Autonomous & Electric Vehicles vs uniQure N.V. Ordinary Shares — how do they compare? Global X Autonomous & Electric Vehicles trades at $30.92 (market cap $357.19M), while uniQure N.V. Ordinary Shares trades at $20.71 (market cap $1.45B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 4.1× Global X Autonomous & Electric Vehicles's market cap, and Global X Autonomous & Electric Vehicles is more actively traded (16,483 versus 3,323,243). Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 41 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| DRIV | QURE | |
|---|---|---|
Market Cap | $357.19M | $1.45B |
Volume | 16,483 | 3,323,243 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $70.59 |
52-Week Low | $27.60 | $9.03 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $32.06, down slightly by 0.06% today. Technical indicators show mixed signals with a bullish overall signal but bearish moving averages. The stock faces resistance at $34 with support at $33. Recent news highlights automotive sector dynamics including hybrid vehicle growth and China's EV ambitions, which could impact DRIV's market positioning.
The outlook for DRIV is cautiously optimistic given sector tailwinds from hybrid and EV adoption, though key financial ratios remain unavailable for fundamental assessment. Risks include oil price volatility and competitive pressures. Analyst sentiment appears balanced with equal buy/sell technical signals, suggesting investors should monitor upcoming earnings for clearer direction.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →